Expression of PD-L1 and its clinical significance in colorectal cancer
DU Zhou1, HUANG Ping2, HUANG Guoyu3, HAN Shaoliang3, ZUO Zhigui4.
1.Department of Hernia and Abdominal Wall Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China; 2.Office of Development and Planning, Wenzhou Medical University, Wenzhou 325035, China; 3.Department of Gastrointestinal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China; 4.Department of Colorectal Anal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China
DU Zhou,HUANG Ping,HUANG Guoyu, et al. Expression of PD-L1 and its clinical significance in colorectal cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2020, 50(1): 41-44.
Abstract：Objective: To investigate the expression of PD-L1 in colorectal cancer and its relationship with clinicopathologic features, and meanwhile to discuss the clinical significance of PD-L1 expression. Methods:Colorectal cancer tissues and adjacent normal tissues were obtained from 50 patients with colorectal cancer. RTPCR and Western blot were conducted to detect the expression of PD-L1 in mRNA and protein levels. Results:The expression of PD-L1 in colorectal cancer tissues was elevated, compared with that in adjacent normal tissues (P<0.05). The elevated expression of PD-L1 in colorectal cancer tissues was correlated with cancer differentiation degree and lymphatic metastasis (P<0.05). Conclusion: PD-L1 was highly expressed in colorectal cancer patients, which was correlated with the clinicopathologic features.
[1] 许剑民, 钟芸诗. 多学科治疗团队在管理和治疗结直肠癌肝转移患者中的作用[J]. 中华胃肠外科杂志, 2010, 13(8): 565-568.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] WANG Q, HUANG Z, NI S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer[J]. PLoS One, 2012, 7(9): e44398.
[4] FERRONE S, WHITESIDE T L.Tumor microenvironment and immune escape[J]. Surg Oncol Clin N Am, 2007, 16(4): 755-774.
[5] FAGARASAN S, HOILJO T. T-indepent immune response: New aspects of B cell biology[J]. Science, 2001, 290(8): 89-92.
[6] MALASPINA T S, GASPAROTO T H, COSTA M R, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma[J]. Cancer Immunol Immunother, 2011, 60(7): 965-974.
[7] SASIDHARAN NAIR V, TOOR S M, TAHA R Z, et al. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer[J]. Clin Epigenetics, 2018, 10(1): 104.
[8] 赵晓敏, 李云涛, 季国忠. 结直肠癌筛查现状与进展[J]. 中国临床研究, 2016, 29(6): 838-841.
[9] SISIK A, KAYA M, BAS G, et al. CEA and CA19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients[J]. Asian Pac J Cancer Prev, 2013, 14(7): 4289-4294.
[10] HOSHINO N, HASEGAWA S, HIDA K, et al. Nomogram for predicting recurrence in stage II colorectal cancer[J]. Acta Oncol, 2016, 55(12): 1414-1417.
[11] SWAIKA A, HAMMOND W A, JOSEPH R W. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy[J]. Mol Immunol, 2015, 67(2 PtA): 4-17.
[12] 吴圣, 邵婧怡, 王芳, 等. PD-L1和PD-1在胃癌组织中的表达及其临床意义[J]. 安徽医科大学学报, 2015, 50(6): 821-825.
[13] HUA D, SUN J, MAO Y, et al. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carci-noma[J]. World J Gastroenterol, 2012, 18(9): 971-978.
[14] MUENST S, SOYSAL S D, GAO F, et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer[J]. Breast Cancer Res Treat, 2013, 139(3): 667-676.
[15] KANG M J, KIM K M, BAE J S, et al. Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma[J]. Transl Oncol, 2013, 6(3): 282-289.
[16] ZHANG Y, HUANG S, GONG D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer[J]. Cell Mol Immunol, 2010, 7(5): 389-395.
[17] ARMAND P, NAGLER A, WELLER E A, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial[J]. J Clin Oncol, 2013, 31(33): 4199-4206.
[18] ZITVOGEL L, KROEMER G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy[J]. Oncoimmunology, 2012, 1(8): 1223-1225.
[19] LIN G, FAN X, ZHU W, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer[J]. Oncotarget, 2017, 8(48): 83986-83994.
[20] TOPALIAN S L, TAUBE J M, ANDERS R A, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16: 275-287.
[21] 张占芳, 张秋堂, 邢海洲, 等. PD-L1在急性白血病中的表达及其临床意义[J]. 中国实验血液学杂志, 2015, 23(4): 930-934.
[22] WANG L, MA Q, CHEN X, et al. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma[J].World J Surg, 2010, 34(5): 1059-1065.
[23] BOUSSIOTIS V A. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med, 2016, 375(18): 1767-1778.
